Share on StockTwits

Tekmira Pharmaceuticals (NASDAQ:TKMR)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a report released on Thursday, ARN reports. They currently have a $31.00 price target on the stock, down from their previous price target of $37.00. Stifel Nicolaus’ price target would suggest a potential upside of 157.90% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at TheStreet downgraded shares of Tekmira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 11th. Separately, analysts at RBC Capital initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Friday, April 11th. They set an “outperform” rating and a $30.00 price target on the stock. Finally, analysts at Maxim Group raised their price target on shares of Tekmira Pharmaceuticals from $17.00 to $31.00 in a research note on Monday, February 24th. They now have a “buy” rating on the stock.

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) traded down 3.74% during mid-day trading on Thursday, hitting $11.57. 74,871 shares of the company’s stock traded hands. Tekmira Pharmaceuticals has a 1-year low of $4.61 and a 1-year high of $31.48. The stock has a 50-day moving average of $16.22 and a 200-day moving average of $14.15. Tekmira Pharmaceuticals also was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 1,139,337 shares, an increase of 29.6% from the April 15th total of 879,324 shares. Currently, 6.6% of the shares of the company are short sold. Based on an average trading volume of 566,050 shares, the short-interest ratio is presently 2.0 days.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.